trending Market Intelligence /marketintelligence/en/news-insights/trending/A24JNWZC8buvv-oj2WosUg2 content esgSubNav
In This List

Biohaven Pharmaceutical files for IPO of up to $100M

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Biohaven Pharmaceutical files for IPO of up to $100M

Biohaven Pharmaceutical Holding Co. Ltd. filed for an IPO of up to $100 million with the U.S. SEC.

The biopharmaceutical company also applied to list on the NYSE under the symbol BHVN, according to the April 7 filing.

Morgan Stanley & Co. LLC and Piper Jaffray & Co. are acting as representatives for the underwriters of the proposed offering, which include Barclays Capital Inc., William Blair & Co. LLC and Needham & Co. LLC.